Evotec to acquire DeveloGen for €14 million plus milestones
This article was originally published in Scrip
Executive Summary
Evotec has bolstered its partnering strategy for drug discovery and early development with a definitive agreement to acquire fellow German firm DeveloGen, a biopharmaceutical company focused on metabolic and endocrine disorders, for up to €14 million in shares plus future performance-related cash payments.